hydroxychloroquine has been researched along with B-Cell Chronic Lymphocytic Leukemia in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The evolving pandemic of Coronavirus Disease 2019 has posed a substantial health risk worldwide." | 1.56 | A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece. ( Argyraki, A; Boletis, I; Grigorakos, K; Lourida, P; Marinaki, S; Skalioti, C; Tsiakas, S, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Baumann, T | 1 |
| Delgado, J | 1 |
| Montserrat, E | 1 |
| Marinaki, S | 1 |
| Tsiakas, S | 1 |
| Skalioti, C | 1 |
| Lourida, P | 1 |
| Argyraki, A | 1 |
| Grigorakos, K | 1 |
| Boletis, I | 1 |
| Torregrosa Calatayud, JL | 1 |
| Garcías Ladaria, J | 1 |
| Sánchez Carazo, JL | 1 |
| Alegre de Miquel, V | 1 |
| Mansilla, E | 1 |
| Marin, GH | 1 |
| Nuñez, L | 1 |
| Drago, H | 1 |
| Sturla, F | 1 |
| Mertz, C | 1 |
| Rivera, L | 1 |
| Ichim, T | 1 |
| Riordan, N | 1 |
| Raimondi, C | 1 |
| Lagneaux, L | 2 |
| Delforge, A | 2 |
| Dejeneffe, M | 1 |
| Massy, M | 2 |
| Bernier, M | 2 |
| Bron, D | 2 |
| Carlier, S | 1 |
6 other studies available for hydroxychloroquine and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report.
Topics: Adenine; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Betacoronavi | 2020 |
A Patient with Cryoglobulinemic Membranoproliferative GN (MPGN) Who Survived COVID-19 Disease: Case Presentation and Current Data of COVID-19 Infection in Dialysis and Transplanted Patients in Greece.
Topics: Anti-Bacterial Agents; Azithromycin; Betacoronavirus; Ceftriaxone; Coronavirus Infections; COVID-19; | 2020 |
[Melkersson-Rosenthal syndrome].
Topics: Aged; Biopsy; Doxycycline; Drug Therapy, Combination; Edema; Female; Humans; Hydroxychloroquine; Leu | 2013 |
The lysosomotropic agent, hydroxychloroquine, delivered in a biodegradable nanoparticle system, overcomes drug resistance of B-chronic lymphocytic leukemia cells in vitro.
Topics: Cell Survival; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Hydroxychloroquine; Leukemi | 2010 |
Hydroxychloroquine-induced apoptosis of chronic lymphocytic leukemia involves activation of caspase-3 and modulation of Bcl-2/bax/ratio.
Topics: Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspases; Cell Survival; Enzyme Activation; Humans | 2002 |
Early induction of apoptosis in B-chronic lymphocytic leukaemia cells by hydroxychloroquine: activation of caspase-3 and no protection by survival factors.
Topics: Aged; Aged, 80 and over; Antirheumatic Agents; Apoptosis; Caspase 3; Caspases; Dose-Response Relatio | 2001 |